Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Parker

Pulmonary Disease Thibodaux, LA Medical Doctor

NPI 1326208232 CMS profile 1113130

604 N Acadia Rd Ste 411, Thibodaux, LA 70301

Open in the dashboard

General payments

$10,150

513 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Parker of Thibodaux, LA is reported in the CMS Open Payments database as having received $10,150 across 513 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,320 67
2024 General $1,412 68
2023 General $1,721 88
2022 General $1,784 85
2021 General $1,221 51
2020 General $1,028 50
2019 General $1,664 104

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Parker
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Brian Parker were reported at $1,320. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Brian Parker Pulmonary Disease median Middle half National median
2019 $1,664 $377 $109–$1,340 $163
2020 $1,028 $230 $56–$907 $114
2021 $1,221 $269 $68–$1,072 $132
2022 $1,784 $390 $100–$1,457 $149
2023 $1,721 $419 $114–$1,659 $160
2024 $1,412 $476 $123–$1,818 $164
2025 $1,320 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $3,200 180 payments
  2. AstraZeneca Pharmaceuticals LP $2,092 90 payments
  3. Genzyme Corporation $883 37 payments
  4. Regeneron Healthcare Solutions, Inc. $752 28 payments
  5. Grifols USA, LLC $589 35 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $565 37 payments
  7. Amgen Inc. $393 15 payments
  8. Mylan Specialty L.P. $225 13 payments
  9. Actelion Pharmaceuticals US, Inc. $190 10 payments
  10. Sunovion Pharmaceuticals Inc. $171 10 payments
  11. Other $1,090 58 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,150 513 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $2,156 122 payments
  2. DUPIXENT Immunology $831 34 payments
  3. DUPIXENT Inflammation And Immunology $726 27 payments
  4. BREZTRI $662 22 payments
  5. Prolastin-C Liquid $589 35 payments
  6. NUCALA $446 32 payments
  7. FASENRA $429 20 payments
  8. SPIRIVA RESPIMAT $407 30 payments
  9. TEZSPIRE Inflammation $393 15 payments
  10. TEZSPIRE Respiratory $362 14 payments
  11. Other $3,946 206 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

2,918

Median for Pulmonary Disease: 936

Drug cost

$1,472,580

Median for Pulmonary Disease: $487,987

Branded share of claims

82.2%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 744 $514,941
Ofev Nintedanib Esylate Brand 17 $219,162
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 195 $137,915
Nucala Mepolizumab Brand 22 $104,579
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 194 $103,243
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 158 $85,591
Breo Ellipta Fluticasone/Vilanterol Brand 194 $84,395
Pirfenidone Generic 12 $77,171
Dupixent Syringe Dupilumab Brand 14 $61,809
Symbicort Budesonide/Formoterol Fumarate Brand 96 $23,050

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$106,137

Of which drugs: $4,197

Medicare patients

510

Average age 75

Services billed

1,549

270 women, 240 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 55%
COPD 54%
Arthritis 47%
Diabetes 40%
Chronic kidney disease 38%
Heart failure 35%
Depression 34%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 29 30 $2,131

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $280
  • Regeneron Healthcare Solutions, Inc. $139
$419 14 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $322
$322 744 —
TEZSPIRE
  • Amgen Inc. $153
  • AstraZeneca Pharmaceuticals LP $37
$190 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $123
$123 — —
Prolastin-C Liquid
  • Grifols USA, LLC $83
$83 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

513 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record